Group 1 - The core point of the article is that Xuantai Pharmaceutical announced its participation in the national organized procurement for drugs whose agreements have expired, specifically regarding the procurement of ursodeoxycholic acid capsules [2] - The company received notification from the procurement office on February 10, 2026, indicating that its product is proposed to be selected in the continuation of the procurement process [2]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

上海宣泰医药科技股份有限公司自愿披露 关于公司产品拟中选国家药品接续采购的公告 证券代码：688247 证券简称：宣泰医药 公告编号：2026-008 三、风险提示 公司拟中选产品的采购合同签订等后续事项以及带量采购后市场销售执行 情况尚具有不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义 务，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 2026 年 2 月 11 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）参与了国家组 织集采第 1-8 批协议期满品种接续采购的申报，根据国家组织集采药品协议期满 品种接续采购办公室（以下简称"接续采购办公室"）于 2026 年 2 月 10 日发布 的《国家组织集采药品协议期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》 显示，公司产品熊去氧胆酸胶囊拟中选本次接续采购，现将相关情况公告如下： 注：上述信息均以接续采购办公室发布的最终中选数据为准。 二、本次拟中选对公司的影响 本次第 1-8 ...

Core Viewpoint - The company Xuantai Pharmaceutical (688247.SH) has announced its participation in the national centralized procurement for the continuation of products whose agreements have expired, with its product ursodeoxycholic acid capsules expected to be selected in this procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the national centralized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Market Impact - The procurement process prioritizes the use of selected drugs by medical institutions, ensuring the completion of the agreed purchase volume [1] - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products, increase market share, and enhance brand influence [1] - This development is expected to have a positive impact on the company's future operating performance [1]

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the national centralized procurement for the continuation of products from the first to eighth batches, with its product, ursodeoxycholic acid capsules, being proposed for selection in the continuation procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the continuation procurement of products whose agreements have expired, as announced by the continuation procurement office on February 10, 2026 [1] - The proposed selection of the company's product indicates a potential for increased sales and market share [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will likely enhance the sales scale and brand influence, positively affecting future operational performance [1]

Core Viewpoint - Xuantai Pharmaceutical (688247.SH) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with its product, ursodeoxycholic acid capsules, being proposed for selection in this procurement process [1] Group 1: Procurement Participation - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products [1] - The selection is expected to increase the company's market share and enhance brand influence, positively impacting future operating performance [1]

Group 1 - Fangda Carbon plans to acquire 100% equity of Tianjin Tongda Huanyu Logistics Co., Ltd. for 319 million yuan [1] - Xiamen Tungsten intends to acquire 39% equity of Jiujiang Dadi Mining Development Co., Ltd. and has signed an intention agreement with a transferor [6] - Wenkai Co. has won a bid for a landscape project worth 50.8162 million yuan [7] Group 2 - Changchun High-tech's subsidiary Jin Sai Pharmaceutical received approval for a clinical trial application for GenSci136, a treatment for IgA nephropathy [3] - China National Pharmaceutical has received drug registration certificates for fumaric acid volnoral tablets, used for treating reflux esophagitis [12] - Zhenhua Group plans to issue convertible bonds not exceeding 1.2 billion yuan [26] Group 3 - CSG Holding's stock may undergo a control change due to share pledge judicial transfer [30] - Ningbo Yunsheng plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [19] - Keda Guochuang's controlling shareholder intends to transfer 5% of the company's shares through an agreement [28] Group 4 - A number of companies, including Finer Pharma, Yixing Guoyuan Investment, and others, have announced plans to reduce their shareholdings by various percentages [2][4][9][11][15][16][20][21][22][23][25][29] - Highweida plans to repurchase shares worth 30 to 35 million yuan [17] - ST Zhongzhu is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [24] Group 5 - A number of companies, including Jiekang Equipment and others, have faced legal issues or penalties [27][40] - Aclaris Therapeutics has clarified that reports regarding its robotic products entering mass production were misinterpreted [41]

Industry News - The Ministry of Transport's new regulatory meeting addressed issues with Gaode Taxi, highlighting management shortcomings and requiring immediate corrective actions to protect driver rights [41] - The Ministry of Commerce held a meeting with automotive companies to discuss strategies for enhancing automotive consumption, including the implementation of a vehicle trade-in program and industry management improvements by 2026 [41] - Apple plans to launch a new iPhone Flip model following the iPhone Fold, prompting Samsung Display to evaluate expanding OLED panel production capacity for Apple [41] - Rare earth product prices have increased, with praseodymium-neodymium oxide averaging 798,800 yuan/ton, up 41,300 yuan/ton; neodymium metal averaging 976,300 yuan/ton, up 61,900 yuan/ton; dysprosium oxide averaging 1,400,800 yuan/ton, up 16,500 yuan/ton; and terbium oxide averaging 6,214,300 yuan/ton, up 77,200 yuan/ton [41][42] Company News - Zhiguang Electric announced a contract for the sale of energy storage systems worth 1.004 billion yuan [43] - Zhejiang Longsheng reported a price increase of 5,000 yuan/ton for certain disperse dyes as of February 8 [43] - Source Technology plans to invest 1.251 billion yuan in the second phase of its optical communication semiconductor chip and device R&D production base [48] - Jinwei Co. intends to acquire 100% of Fusheng Mining for 210 million yuan, with the target company holding mining rights for a production scale of 50,000 tons/year [48]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688247 证券简称：宣泰医药 公告编号：2026-007 上海宣泰医药科技股份有限公司持股5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 大股东持股的基本情况 截至本公告披露日，上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）股东Finer Pharma Inc.（以下简称"Finer"）持有公司股份70,437,870股，占公司总股本的15.5375%。上述股份来源 为公司首次公开发行前取得的股份，已于2025年8月25日解除限售并上市流通。 ● 减持计划的主要内容 公司于2026年2月9日收到Finer出具的《关于上海宣泰医药科技股份有限公司股份减持计划的告知 函》，因股东自身资金需求，Finer计划根据市场情况拟通过集中竞价或大宗交易的方式减持其所持有 的公司股份数量合计不超过9,066,800股，拟减持股份数量占公司总股本的比例不超过2.0000%。其中以 集中竞价方式减持的，减 ...

Group 1 - The controlling shareholder of Bowei Alloy plans to increase its stake in the company by 100 million to 150 million yuan [1] - The actual controller and directors of Congsheng Co. intend to reduce their holdings by no more than 5% of the company's shares [1] - Yinbei Investment of Senba Sensor plans to reduce its stake by no more than 3% of the company's shares [1] Group 2 - The controlling shareholder and its concerted parties of Liansheng Chemical plan to reduce their holdings by no more than 3% of the company's shares [1] - A shareholder of ST Zhongzhu intends to reduce its stake by no more than 3% of the company's shares [1] - Shareholders of Youde Precision (rights protection) plan to collectively reduce their holdings by no more than 3% of the company's shares [1] Group 3 - Shareholder Finer of Xuantai Pharmaceutical plans to reduce its stake by no more than 2% of the company's shares [1] - A shareholder of Far East Co. intends to reduce its holdings by no more than 1.5% of the company's shares [1] - A shareholder of Zhongzhou Special Materials plans to reduce its stake by no more than 1.4% of the company's shares [1] Group 4 - Qianhai Jin控 plans to reduce its stake in GCL-Poly Energy by no more than 1.01% of the company's shares [1] - The controlling shareholder of Keda Technology intends to reduce its holdings by no more than 1% of the company's shares [1] - Yulong Venture Capital plans to reduce its stake in Haiguo Co. by no more than 0.9965% of the company's shares [1] Group 5 - Shareholders of Lian Technology plan to collectively reduce their holdings by no more than 0.96% of the company's shares [1] - The controlling shareholder of Teda Co. intends to reduce its holdings by no more than 29.38 million shares [1] - The actual controller of Perfect World reduced its stake by 1.247 million shares during a period of abnormal stock fluctuations [1] Group 6 - A shareholder of Tengya Precision plans to reduce its stake by no more than 3.8 million shares [1]